Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial

Abstract Introduction The dismal prognosis of pancreatic ductal adenocarcinoma (PDAC) highlights the urgent need for novel therapeutic strategies. Immune checkpoint inhibitors (ICIs) seem to be ineffective in most PDAC studies. Therefore, we conducted an open-label, multicenter phase 1/2 study (CA20...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Milan Vošmik, Stanislav John, Josef Dvořák, Beatrice Mohelníková-Duchoňová, Bohuslav Melichar, Radka Lohynská, Aleš Ryška, Aml Mustafa Banni, Johana Krempová, Igor Sirák
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Adis, Springer Healthcare 2024-10-01
Schriftenreihe:	Oncology and Therapy
Schlagworte:	Pancreatic ductal adenocarcinoma Stereotactic radiotherapy Nivolumab
Online-Zugang:	https://doi.org/10.1007/s40487-024-00309-z
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!